Receipt of formal meeting minutes from the FDA confirming key elements for two proposed Phase 3 pivotal trials indicates regulatory progress and alignment with the FDA. Positive outcome of the ...
CEO George Lasezkay highlighted the company's progress in advancing its suprachoroidal delivery platform, noting over 15,000 suprachoroidal injections performed to date. He announced alignment with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results